New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
12:25 EDTILMN, ILMN, LIFE, LIFE, FLDM, FLDM, PACB, PACBLeerink's life science tools and diagnostics analyst to hold a conference call
Life Science Tools & Diagnostics Analyst Dan Leonard provides a recap on sequencing from the Advances in Genome Biology & Technology (ASBT) Meeting, recently held on Marco Island, on an Analyst/Industry conference call. Relevant covered companies Illumina, Life Technologies, Fluidigm and Pacific Biosciences of California to be discussed on the Analyst/Industry conference call to be held on February 25 at 1 pm.
News For ILMN;LIFE;FLDM;PACB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
09:44 EDTILMNIllumina participates in a conference call with JPMorgan
Subscribe for More Information
May 22, 2015
16:28 EDTLIFEPolaris Venture Partners reports 8.2% stake in aTyr Pharma
Subscribe for More Information
May 19, 2015
09:18 EDTILMNBofA/Merrill life sciences analysts hold an analyst/industry conference call
Analysts, along with Nancy J. Kelley, a nationally recognized executive and lawyer who has championed the field of Synthetic/Engineering Biology in the U.S., discuss what Synthetic Biology is and whether it will disrupt the Healthcare landscape and how Synthetic Biologic-based products would be regulated on an Analyst/Industry conference call to be held on May 19 at 2 pm.
May 18, 2015
16:07 EDTILMNIllumina files new patent infringement suit against Roche unit
Subscribe for More Information
06:38 EDTFLDMFluidigm shares offer attractive entry point, says Leerink
Leerink believes the current share of Fluidigm represents an attractive entry point ahead of the company's new product launches. The firm thinks Fluidigm is well positioned to benefit from the growth in single cell analysis. It keeps an Outperform rating on the name with a $45 price target.
May 15, 2015
16:22 EDTLIFESofinnova Venture Partners IX reports 8.3% stake in aTyr Pharma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use